Please login to the form below

Not currently logged in
Email:
Password:

BMS and Pfizer's Eliquis in trial success

Bristol-Myers Squibb and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation 

Bristol-Myers Squibb (BMS) and Pfizer have revealed successful topline results of the phase III ARISTOTLE trial of Eliquis (apixaban) for atrial fibrillation. 

In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, Eliquis met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. 

The drug met the key secondary endpoints of superiority on efficacy and on International Society on Thrombosis and Hemostasis major bleeding compared to warfarin.

Eliquis, a new oral direct Factor Xa inhibitor, is being developed by the alliance of BMS and Pfizer.

The companies expect to submit regulatory filings in atrial fibrillation in the US and Europe in the third or fourth quarter of 2011.

The detailed results of the ARISTOTLE study will be presented on August 28 at the European Society of Cardiology Congress 2011 in Paris.

23rd June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics